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Abstract Deubiquitylating enzymes (DUBs), act down-
stream of ubiquitylation. As such, these post-post-
translational modifiers function as the final arbitrators of a
protein substrate’s ubiquitylation status, thus regulating its
fate. In most instances, DUBs moderate the absolute level
of a substrate, its locality or activity, rather than being an
‘‘all-or-none’’ phenomenon. Yet, disruption of this quan-
titative regulation can produce dramatic qualitative
differences. The ubiquitin-specific protease 9X (USP9X/
FAM) is a substrate-specific DUB, which displays an ex-
traordinarily high level of sequence conservation from
Drosophila to mammals. It is primarily the recent revela-
tions of USP9X’s pivotal role in human cancers, both as
oncogene or tumour suppressor, in developmental disor-
ders including intellectual disability, epilepsy, autism and
developmental delay that has led to a subsequent re-ex-
amination of its molecular and cellular functions. Results
from experimental animal models have implicated USP9X
in neurodegeneration, including Parkinson’s and Alzhei-
mer’s disease, as well as autoimmune diseases. In this
review, we describe the current and accumulated knowl-
edge on the molecular, cellular and developmental aspects
of USP9X function within the context of the biological
consequences during normal development and disease.
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Introduction
A large part of tissue development regulation and ho-
moeostasis concerns the precise control of cell numbers,
morphology and function in response to local or systemic
signals. These phenomena are regulated at multiple levels
including post-translational modifications (PTMs), which
determine protein function, including localisation, activity,
stabilisation and fate. The key characteristics of PTMs are
that they are rapid and reversible allowing cells to regulate
signalling pathways in response to environmental condi-
tions, through the quantitative regulation of substrate
function. One of the best-studied PTMs is ubiquitylation in
which proteins are covalently linked to the 76 amino acid
protein, ubiquitin. Initially described as a tag for degrada-
tion, ubiquitylation has emerged as a dynamic and versatile
PTM, which regulates most, if not all, cellular processes
(see [1, 2] for reviews). Ubiquitylation is a reversible
process where the deconjugation of ubiquitin is performed
by a family of enzymes called deubiquitylases (DUBs).
There are approximately 95 DUBs encoded by the hu-
man genome [3]. The largest family is the ubiquitin-
specific proteases (USP), which is substrate specific and
precisely regulates cellular processes. This diverse family
of proteins shares a catalytic domain of between 300 and
800 amino acids, which contain two short conserved cys-
teine and histidine catalytic motifs separated by long
stretches of non-conserved intervening sequences. The
catalytic domain is also flanked by non-conserved N- and/
or C-terminal extensions, which impart substrate specificity
[3, 4]. Apart from the conserved catalytic motifs, the USPs
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share little or no similarity; however, USP members per-
form in effect post-PTMs as their substrates are already
post-translationally modified by ubiquitylation. Indeed,
ubiquitylation itself is also often preceded by other PTMs
such as phosphorylation [5] or hydroxylation [6]. There-
fore, the activity and functional relevance of all USPs is
highly context specific, dependent on the activity of the
upstream enzymes, such as E3 ubiquitin ligase or kinases,
performing the preceding PTMs. Despite residing at the
end of a chain of PTMs, USPs are not redundant proteins as
loss of function in nearly all USPs is associated with, often
severe, functional consequences. In this review, we will use
the example of USP9X to illustrate the relevance of
studying this emerging family of ubiquitin-modifying
proteins.
USP9X is a highly conserved DUB
Although USP9X is over 2,550 amino acids in size, very
little is known about the protein structure. Apart from the
USP-definitive cysteine and histidine box catalytic motifs,
the only other recognisable domain is a ubiquitin-like
module (Ubl) in the N-terminal extension (amino acids
886–970) (Fig. 1). It has been proposed that in solution,
USP9X is an elongated monomeric protein [7]. Enzy-
matically, USP9X can cleave mono-ubiquitin from
substrates and a wide variety of ubiquitin chains, including
K48, K63 and K29 linkages, [8–13] and is known to in-
teract with at least 35 proteins, many of which are
substrates (Table 1). The protein sequence of USP9X does,
however, display a remarkable degree of evolutionary
conservation from Drosophila to mammals. Across verte-
brates, the level of conservation of USP9X ([90 %) is
equivalent to that of the developmental master-regulatory
genes, such as Pax6 and b-catenin, and is maintained
across the entire protein [14]. High sequence conservation
of USP9X mirrors its function across species. The first
USP9X homologue identified was the Drosophila gene fat
facets (faf), found in a mutagenesis screen and shown to be
required for the development of the syncytial stage embryo
as well as photoreceptor fate determination [15]. The ex-
pression of mouse Usp9x rescued both eye and embryo
defects in faf mutants, emphasising functional conservation
from flies to mammals [16, 17]. In addition, the expression
of human USP9X rescues axonal and migration defects in
neurons derived from Usp9x conditionally deleted mice
[18]. Thus, USP9X molecular functions are highly con-
served throughout evolution. USP9X is in fact among the
top 500 human genes with the lowest ‘tolerance’ to DNA
variation [19] and exhibits selective constraint over evo-
lution [20]. The discoveries of deleterious USP9X genetic
variants found associated with neurological disorders [18]
and enriched in cancer samples (Fig. 1 and below) are in
line with the strong selection against USP9X mutation.
Cellular functions of USP9X
Knowing USP9X’s cellular functions is a prerequisite for
the understanding of its role in development and disease.
Here, we highlight the diverse and dynamic subcellular
localisation of USP9X before illustrating its involvement in
cellular processes that are fundamental to many aspects of
development and disease, namely protein trafficking, cell
polarity and cell death.
Cellular localisation of USP9X
The intracellular localisation of USP9X is complex, dy-
namic and dependent on cell type and status. In general,
Fig. 1 Structural information of USP9X. Schematic of USP9X
structure showing functional domains and nuclear localisation
sequence (NLS) motifs. Below the schematic are the regions of
USP9X known to facilitate binding to the listed interacting proteins.
Above the schematic is a scale (in amino acids), the localisation of
variants associated with ID18 and a histogram of variants found in
cancer samples (cBioportal). Red indicates nonsense variants, green
represents missense variants and purple indicates both
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Table 1 List of substrates and proteins interacting with USP9X
Substrates Major role of substrate Interaction shown by References
AF-6 Cell adhesion and polarity Co-IP from brain lysates [12, 109]
AGS3 Mitotic spindle orientation
Golgi function




Major component of Lewy bodies
Co-IP SH-SY5Y lysates and rat brain homogenates [86]
ASK1 Apoptosis Co-IP from HEK293A cells [53]
BCL10 Activation of NFjB pathway Co-IP JE6.1 cells [110]
b-Catenin Cell adhesion
Wnt signalling
Co-IP from brain, L, MCF7 and T84 cells [111]
EFA6 Cell adhesion and polarity Co-IP from MDCK cell lysates [23]
Epsin/liquid facets Endocytosis
Notch signalling
Co-IP from brain lysates, Drosophila eye disc protein extracts [32, 35]
ErbB2 Oncogene IP from SK-BR-3 cells [10]
ERG Transcription factor
Prostate cancer
GST pulldowns and Co-IP from VCaP prostate cancer cells [92]
ITCH E3 Ligase Co-IP from HEK293 and GST pulldown from brain lysates [11, 37]
MARCH7 E3 Ligase
Ubiquitin system
Sepharose pulldowns and IP from HEK293 cells [112]
MARK4 Cell adhesion and polarity Tandem affinity purification and Co-IP from HEK293 cells and
brain lysates
[8]
MCL1 Apoptosis Co-IP HEK293T cells [24]
NUAK1 AMPK-related kinase Tandem affinity purification and Co-IP from brain lysates
and HEK293
[8]
PEX5 Peroxisomal protein shuttling IP from rat liver and HeLa cell lysates [7]
SMAD4 TGFb signalling Co-IP from HEK293 [9]
SMURF1 TGFb/BMP signalling pathway Quantitative mass spectrometry and Co-IP from HEK293 lysates [65]
SMN Maintenance of motor neurons Mass spectrometry and Co-IP from HEK293 and HeLa cells [42]
SURVIVIN Mitosis
Apoptosis
Co-IP from Xenopus oocytes and HeLa cells [13]
VASA Transcriptional regulation Yeast two hybrid and tandem immunoprecipitation [113]
Interactor Major role of interactor Interaction shown by References
BAG1 Cell survival Co-IP primary AML cells [60]
DCX Neuronal migration
Trafficking
Co-IP from brain lysates [82]
FOXO3 Transcription factor IP from T74D breast cancer cell line [114]
HDAC6 Transcriptional regulation Mass spectrometry-based proteomics strategy [115]
HUNTINGTIN Trafficking Transcription Yeast two-hybrid and Co-IP from brain [88]
IKAP Neurogenesis and cell migration Mass spectrometry HEK293 cells [116]
Imd Innate immune response Co-immunoprecipitation from S2 cells [117]
Lebercilin Leber congenital amaurosis Quantitative protein complex analysis in HEK293 cells [118]
Mind bomb1 E3 Ligase
Signalling
GST pulldown from neuronal lysates, yeast two-hybrid
screening and Co-IP
[39, 40]
p100 TNFa signalling Tandem affinity purification [119]
SALL4 Self-renewal Mass spectrometry and protein interaction networks [75]
SOX2 Transcription factor with critical roles in
embryonic CNS development
Multi-dimensional protein identification technology in
medulloblastoma cell line
[74]
TANK Type I interferon induction Mass spectrometry and protein interaction network [120]
VMP1 Autophagy Co-IP AR42J acinar cell lysates [121]
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however, immunofluorescence on both cultured and in vivo
cells detects USP9X predominantly in cytoplasmic and
membrane-associated puncta [21–23]. In polarised T84
epithelial cells, USP9X-labelled puncta represented sites of
vesicular protein trafficking, such as the Golgi apparatus,
late endosomes and other cytoplasmic vesicles [22]. In
other epithelial cell lines (MDCK cells), USP9X has also
been detected localised at the cell membrane at the pri-
mordial [23] and mature [12] adhesion junctions. Other
studies report small portions of USP9X present at the mi-
tochondria [24] and in the nucleus [25, 26] as well as a
significant portion in the cytoplasm [22]. USP9X subcel-
lular localisation is dynamic. For example, disrupting
protein trafficking or the Golgi in polarised epithelia results
in relocation or accumulation of USP9X, suggesting that it
circulates between a number of organelles and vesicles
with different resident times at each compartment. Con-
versely, expressing cadherin cell adhesion molecules in
fibroblasts altered USP9X localisation [22]. The existence
of multiple, dynamic pools is consistent with a variety of
cellular USP9X functions regulated by localisation, but
remains poorly characterised. In addition, several USP9X
substrates, for example, EFA6 and AGS3, are also present
in multiple cellular localisations and only a subset of
USP9X and its substrate show spatial colocalisation [23,
27]. These observations highlight the need to interrogate
USP9X/substrate interactions using techniques, which
distinguish specific subcellular compartments as opposed
to more disruptive biochemical approaches used to date
where cellular architecture is destroyed.
USP9X in protein trafficking/endocytosis
Directed protein trafficking through the vesicular network
controls many aspects of cellular morphology, function and
signalling. It is regulated at multiple levels by ubiquityla-
tion, in particular mono-ubiquitylation, which occurs in
both cis and trans [28–30]. In cis, the ubiquitylation status
of cargo proteins (e.g. ligand-activated receptor tyrosine
kinases) can direct vesicular trafficking pathways and
protein fate, whilst in trans the mono- and poly-ubiquity-
lation of vesicular adaptor proteins (e.g. the endocytic
adaptor Epsin) also regulates vesicular transport machin-
ery. Not surprisingly, the role of DUBs in protein
trafficking events has now been recognised [26, 30].
In Drosophila, genetic screening identified liquid facets
(lqf) as faf’s critical substrate in photoreceptor fate deter-
mination [31]. lqf is the Drosophila homologue of Epsin,
an endocytic adaptor protein involved in both clathrin-
mediated and clathrin-independent endocytosis. Faf op-
poses the ubiquitin–proteasome mediated degradation of
Lqf [32]. A disruption in the Delta/Notch signalling events
underlies the eye phenotype observed in faf and lqf null
mutants [33, 34]. Faf regulation of Lqf is essential for a
specific endocytic event (as opposed to bulk endocytosis)
required for the competence of the Notch ligand Delta to
signal [34]. The Usp9x–Epsin interaction has also been
maintained in mammals. Usp9x and Epsin co-immuno-
precipitate from synapses in the rat brain, and evidence
suggests that this interaction is promoted by neuronal ac-
tivity resulting in specific deubiquitylation of Epsin [35].
USP9X also regulates protein trafficking by deubiqui-
tylation of multiple endocytic E3 ligases. The E3 ligase
Itch antagonises the internalisation and trafficking of acti-
vated epidermal growth factor receptor (EGFR) to the
lysosome by promoting the proteasomal degradation of the
endocytic accessory protein endophilin and another E3 li-
gase, Cbl [36–38]. However, Itch also auto-ubiquitylates
the following EGFR activation and requires specific deu-
biquitylation by USP9X to protect itself [11]. Similarly,
Mind bomb’s E3 ubiquitin ligase activity is required for
Delta endocytosis and signalling through Notch, and Mind
bomb also displays auto-ubiquitylating activity and
degradation at the proteasome. USP9X and Mind bomb1
interaction has been shown previously [39, 40]. Interest-
ingly, Mind bomb1 ubiquitylates and catalyses the
proteasomal degradation of SMN [41], a USP9X substrate
[42]. These findings indicate that it is possible for USP9X
and Mind bomb1 to cooperate in the regulation of SMN
protein and in Mind bomb1-regulated endocytic events.
Finally, USP9X is implicated in the regulation of en-
docytosis of the breast cancer oncogene and EGFR family
member ErbB2. In SK-BR3 cells (breast cancer cells
overexpressing ErbB2) treated with the proteasome in-
hibitor bortezomib, ErbB2 co-immunoprecipitates with a
complex containing c-Cbl and USP9X. Reduction in
USP9X levels increases bortezomib-induced downregula-
tion of ErbB2, suggesting that USP9X is associated with
the internalisation and ubiquitylation status of ErbB2 [10].
These data support the roles of USP9X in endocytosis and
downstream events. However, USP9X also colocalises
with markers of the trans-Golgi network in multiple cell
types [22]. The localisation of proteins associated with the
late Golgi compartment is affected in USP9X knockdown
cells possibly by regulating the levels of AGS3 [27]. Fur-
thermore, it is proposed that USP9X regulates the
trafficking of the E-cadherin/b-catenin dimer in epithelial
cells undergoing polarisation [22]. Collectively, these
studies strongly suggest that USP9X plays an important
role in the regulation of protein trafficking at multiple
points in the cell.
USP9X regulation of polarity
Cell polarity underpins many aspects of normal tissue
growth and morphogenesis, and deregulation is a feature of
2078 M. Murtaza et al.
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many disorders, including tumourogenesis and metastasis.
There are two types of polarity: apical–basal and planar
cell polarity (PCP), and USP9X is implicated in both. PCP
is the polarisation of epithelial cells within the plane
orthogonal to their apical–basal axes. Core PCP proteins
instruct these polarised cell movements [43], and
Drosophila genetics has revealed that faf acts upstream in
this process [44]. Apical–basal polarity in epithelia is
established and maintained via three inter-dependent pro-
cesses: cell–cell adhesion, activated cell polarity
complexes and polarised protein trafficking. The estab-
lishment of adherens junctions (AJs) and subsequently tight
Junctions (TJs) is considered the pioneering event and
multiple studies have implicated USP9X in this process.
Depleting USP9X disrupts TJ assembly in MDCK epithe-
lial cells, an effect mediated through EFA6. In these cells,
USP9X is required to deubiquitylate EFA6 resulting in
localised stabilisation of EFA6, thereby promoting de novo
assembly of TJs [23, 45]. USP9X also co-localises and
binds to AF-6, a critical regulator of intercellular junctions
and a similar colocalisation is observed in the developing
eye [12, 46]. In pre-implantation embryos, USP9X deple-
tion results in a failure of blastomere compaction, which is
associated with mislocalisation of AF6 to apical surfaces,
indicative of a polarity defect [47]. In the highly polarised
neural progenitor cells of the developing brain, USP9X is
apically enriched and again partially colocalises with cell
junction proteins b-catenin and N-cadherin. Overexpres-
sion of USP9X in embryonic stem cell (ESC)-derived
neural progenitors promoted their polarisation in vitro [21].
Other studies describe USP9X in the regulation of adhesion
junctions more generally, with indirect implications for
polarity. For example, USP9X also colocalises with adhe-
sion proteins such as b-catenin, p120 catenin, E-cadherin
and ZO-1 in the polarised human intestinal cell line T84.
Interestingly, USP9X physically interacts with b-catenin (a
known substrate) and E-cadherin only in subconfluent cells
where adhesion junctions are undergoing dynamic rear-
rangements, and not in confluent cells exhibiting mature
adhesion junctions [22]. In MDCK cells, overexpression of
the USP9X catalytic domain increased the steady-state
levels of b-catenin, presumably by its ability to deubiqui-
tylate and hence rescue from proteasomal degradation.
However, a partial knockdown of USP9X did not affect the
protein levels of b-catenin [23], suggesting a concentra-
tion- dependent role for USP9X–b-catenin regulation.
Together, these studies show that USP9X interacts with
multiple cell adhesion proteins, and that cell adhesion (and
polarity) is itself sensitive to changes in USP9X
expression.
Downstream of adhesion, cell polarity complexes are
activated that orchestrate the establishment and mainte-
nance of apical–basal polarity. Genetic and molecular
evidence has revealed the importance of the highly con-
served Par family of proteins as components of these
polarity complexes [48]. USP9X binds to the AMP-acti-
vated protein kinase (AMPK)-related kinases NUAK1 and
MARK4 (Par-1 homologues) [8, 49]. The family of
AMPK-related kinases are activated by the LKB1 kinase
(Par-4 homologue), and are known to regulate polarity
[50]. NUAK1 and MARK4 are substrates of USP9X, and
the resultant deubiquitylation of these two kinases pro-
motes their phosphorylation and activation by LKB1 [8],
suggesting USP9X might regulate their activities during
the establishment and maintenance of polarity. Further
evidence suggests that USP9X is also important for po-
larised vesicular trafficking (see above). Together, these
studies reveal that USP9X is important for polarity, inter-
acting genetically with core PCP genes and molecularly at
multiple stages of apical–basal polarity, including estab-
lishment of cell adhesion complexes and the regulation of
polarity complexes.
USP9X and cell death
Apoptosis is an integral part of development and disease
and involves a highly regulated sequence of events. USP9X
has been shown to regulate both pro- and anti-apoptotic
pathways. Regarding its pro-apoptotic activities, three in-
dependent lines of evidence implicate USP9X. In
Drosophila, faf has been identified as a dominant enhancer
of apoptosis induced by either the Grim or Reaper proteins
[51, 52]. Coexpression of Reaper or Grim with faf in the
Drosophila CNS midline results in a dramatic reduction in
midline glia and neurons [52] indicative of a pro-apoptotic
role for faf. In mammalian cells, USP9X has been shown to
regulate the levels of stress-sensing pro-apoptotic kinases
that initiate the apoptotic JNK signalling cascade. In re-
sponse to extracellular and intracellular stress (for example,
oxidative stress), the pro-apoptopic kinase, apoptosis sig-
nal-regulating kinase1 (ASK-1), is activated resulting in
the selective activation of the JNK and p38 MAPK path-
ways. USP9X binds ASK-1 and protects it from
proteasomal degradation. In USP9X-depleted cells, acti-
vation of JNK and p38 was reduced and oxidative stress-
induced cell death was decreased [53]. A similar role for
USP9X was also found in the regulation of DLK kinase,
which is activated and stabilised (by USP9X) at sites of
stress in neurons (e.g. injury or removal of trophic support),
enabling it to activate pro-apoptotic JNK signalling [54].
Conversely, USP9X is known to promote the activities
of anti-apoptotic factors, MCL1 and Survivin. MCL1 is a
member of the anti-apoptotic BCL2 family that is essential
for promoting the survival of multiple cell types [55–57].
USP9X deubiquitylates poly-ubiquitylated MCL1, pro-
tecting it from proteasomal degradation, thus increasing its
USP9X in development and disease 2079
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stability and thereby promoting cell survival. USP9X de-
pletion increases poly-ubiquitylation of MCL1, enhances
its turnover and sensitises tumour cell lines to the pro-
apoptotic drug ABT-737 (a BCL2 antagonist that does not
target MCL1) [24]. Interestingly, synergistic enhancement
of the pro-apoptotic effects of ABT-737 also occurs when
used in combination with gemcitabine, the addition of
which was specifically associated with a disruption of the
USP9X–MCL1 interaction [58]. Increased MCL1 turnover
and sensitivity to apoptotic stimuli is also reported in
chronic myelogenous leukaemia (CML) cells following
USP9X depletion [59]. In addition, studies conducted in
acute myeloid leukaemia (AML) cells, the anti-apoptotic
activity of the BCL2-associated athanogene-1 (BAG1) was
suggested to occur via USP9X and MCL1; BAG1 was
found to immunoprecipitate with both USP9X and MCL1,
and reduced BAG1 expression resulted in the depletion of
both and associated with elevated MCL1 ubiquitylation
[60]. Thus in multiple cancer cell types, the level at which
USP9X is able to deubiquitylate and stabilise MCL1 dic-
tates its anti-apoptotic function. USP9X also interacts with
the anti-apoptotic factor survivin [13, 61], although the
relevance of this interaction in the context of apoptosis has
not been addressed. Collectively, the data suggest that
USP9X can function at multiple stages during initiation
and execution of the pathways involved in cell death. It can
display both pro- and anti-cell death functions, mediated by
the ability of USP9X to deubiquitylate the critical com-
ponents of the apoptotic signalling networks.
USP9X in development
The initial investigations of Faf showed that it was required
for cell fate decisions of the developing eye [15]. The
discovery of Usp9x in mouse was the result of gene-trap
screen of genes expressed during early embryonic devel-
opment [17]. Thus from its origins, USP9X has been
implicated in developmental processes and recent investi-
gations have identified multiple requirements during
embryogenesis, with particular focus on USP9X’s roles in
stem cells and neural development.
USP9X in embryogenesis
Usp9x is essential for embryogenesis as both Usp9x-/y
males and even heterozygous Usp9x?/- females display
embryonic lethality [53, 62]. USP9X is required from the
earliest stages of development. Depletion of USP9X from
two-cell mouse embryos halts development at the blasto-
cyst stage and results in slower blastomere cleavage rate,
impaired cell adhesion and a loss of cell polarity [47]. The
early requirement of USP9X in embryonic development is
also evident in Drosophila, where faf is required for the
initial cellularisation and polarity of syncytial embryos
[15]. At gastrulation, Usp9x is required for mesoderm
formation, at least in Xenopus, through its regulation of
TGFb signalling. Usp9x promotes TGFb pathway sig-
nalling by deubiquitylating Smad4, allowing it to complex
with phosphorylated receptor Smads and then shuttle into
the nucleus to execute transcriptional responses to TGFb
family ligands [9]. Faf regulation of TGFb signalling also
regulates threshold responses to morphogens (decapenta-
plegic) during dorso-ventral patterning in Drosophila
embryos [63]. Furthermore, mouse neurons lacking USP9X
fail to respond to TGFb signalling [64]. Intriguingly,
USP9X also has the potential to negatively influence TGFb
signalling, via the deubiquitylation and stabilisation of the
SMURF1 E3 ligase, which downregulates TGFb receptors
[65].
The regulation of TGF signalling is the best example of
how USP9X’s involvement in signal transduction impacts
developmental processes. As mentioned earlier, USP9X is
also implicated in the Notch, EGF, Wnt and mTOR sig-
nalling pathways and therefore is likely to impact many
other developmental processes. Its position in these path-
ways suggests potential coordination of cellular responses
to multiple signalling inputs (Fig. 2).
In post-gastrulation murine embryos, ubiquitous Usp9x
transcript expression is observed but becomes more com-
plex from mid-gestation until birth. What drives the
complex nature of its expression is however largely un-
known. USP9X gene expression is reportedly regulated by
p53 and p63 [66, 67] and microRNA regulation of USP9X
has also been reported [68]. However, it is unclear under
what circumstances this regulation occurs and its relevance
to developmental expression patterns. In general, high ex-
pression of USP9X is maintained in undifferentiated
progenitor and stem cells and decreases as differentiation
proceeds. For example, USP9X is highly expressed in the
nascent limb buds, but its expression is switched off in a
proximal to distal pattern as differentiation progresses
along the same axis as the limb grows [17]. However,
USP9X is also expressed in cells undergoing apoptosis
between the digits, indicating that USP9X is not only a
stem cell factor. The recent generation of inducible LoxP
based USP9X knockout mice will be a valuable tool for the
ongoing dissection of the role of USP9X during develop-
ment [62, 64].
USP9X and stem cells
Despite wide variations in cell morphologies and functions,
all stem cells are defined by two unique characteristics,
their ability to self-renew and differentiate. These signature
features have been interrogated using transcriptomic
2080 M. Murtaza et al.
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approaches, with the aim of identifying ‘stemness’ genes
based on enriched expression in the stem cell population
compared to immediately derived differentiated progeny.
USP9X has been identified in studies of mouse [69, 70] and
human [71] stem cells including embryonic, neural and
hematopoietic stem cells and adult epidermal stem cell
populations. USP9X was likewise identified using pro-
teomics approaches in both human and mouse ESCs [72,
73]. Consistently, USP9X protein is expressed highly in
stem cells in vivo including blastomeres of pre-implanta-
tion embryos [47] and neural stem cells [21, 64]. Only
recently have studies begun to address the function of
USP9X in stem cell populations. Interestingly, deletion of
USP9X from mouse ESC did not significantly affect their
capacity to be cultured in vitro [53]; however, it may still
regulate early differentiation. USP9X has been detected in
both Oct4 and Sox2 interaction networks [74, 75].
Regulation of these proteins and networks at the post-
translational level by ubiquitylation and deubiquitylation is
important for lineage specification. In muscle stem cells,
USP9X regulation of the mTOR pathway has been shown
to control proliferation and differentiation [76], whilst
USP9X levels also control the behaviour of neural stem
cells (see below). Thus, the proposal based on expression
that USP9X is important for stem cell function is beginning
to be realised in multiple types and warrants broader
interrogation.
USP9X in neural development
USP9X is very highly expressed in neural stem cells/pro-
genitors (NSC/NP) in vivo in both mice [17, 21] and
zebrafish [14] embryos. In the adult brain, USP9X ex-
pression is significantly reduced, but is maintained in the
neural progenitors residing in the adult neurogenic niches
[21, 64]. USP9X expression levels influence NP organisa-
tion and fate both in vivo and in vitro. Nestin-Cre mediated
deletion of Usp9x from neural progenitors, during mouse
central nervous system development, results in a profound
disruption of cortical architecture, particularly affecting the
Fig. 2 Coordination of developmental signalling pathways by
USP9X. Interactors of USP9X (hexagons) are key regulators, or
signal transduction molecules, of signalling pathways important for
many aspects of embryogenesis. In Notch signalling (orange),
USP9X is required in the signal sending cells to antagonise the
proteasomal degradation of both Mind bomb1 (MIB1) and Epsin1,
which control key endocytic events of Notch ligands (Delta, Serrate
and Lag2; DSL) required for signalling competence. In EGF
signalling (dark blue), USP9X protects ITCH from proteasomal
degradation, which then inhibits the delivery of the EGF receptor to
the lysosome and hence promotes signalling output. USP9X interacts
with multiple components of the mTOR signalling pathway (green)
including mTOR, Raptor and Rictor. Although the direct consequence
of these interactions is unknown, Usp9x negatively regulates the
signalling output of the two mTOR signalling complexes, mTORC1
and 2. USP9X can promote canonical Wnt signalling (light blue) by
protecting the central signal transduction component b-catenin (bcat)
from proteasomal degradation, thus promoting its accumulation,
which is associated with nuclear translocation. USP9X can also affect
TGFb signalling (purple) both positively and negatively. USP9X
protects SMURF1 from proteasomal degradation, which enables it to
directly downregulate TGFb receptors from the cell surface. In
contrast, USP9X promotes TGFb signalling by reversing the effects
of mono-ubiquitylation of the common Smad4, which inhibits its
ability to form signal transducing complexes with receptor SMADs (R
SMAD). Adding further complexity, USP9X substrates can them-
selves regulate multiple signalling pathways, for example ITCH also
negatively regulates Notch and Wnt signalling (dark blue dotted
lines), whilst SMURF1 also negatively regulates Wnt signalling
(purple dotted lines)
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proliferative zones containing the NPs [64]. A dramatic
decrease in hippocampal size was also prominent, sug-
gesting that hippocampal NPs are particularly sensitive to
USP9X function [64]. On the other hand, overexpression of
USP9X in cultured, adherent NPs promoted their or-
ganisation into polarised clusters, which was associated
with increases in their self-renewal capacity [21]. There-
fore, consistent with its identification as a stemness gene,
USP9X regulates NPs.
USP9X also regulates the growth and function of post-
mitotic neurons. Deletion of USP9X results in reduced
neuronal outgrowth both in vivo and in cultured hip-
pocampal neurons [18, 64]. In the latter instance,
deregulation of TGFb signalling and cytoskeletal proteins
was suggested to underlie the neuronal growth defects (see
below). Neuronal overexpression of faf induces severe
disruption of synaptic growth control at the neuromuscular
junctions, evident by an increase in the number of synaptic
boutons, elaborate synaptic branching and decreased sy-
naptic transmission. That loss of function lqf mutants
negate the effects of Faf overexpression on synaptic bouton
number suggest deregulated endocytosis may underlie the
altered synaptic growth [77]. In other studies, Faf overex-
pression was found to enhance loss of synaptic boutons
resulting from Par1 overexpression, whereas Faf depletion
rescued the defect. Further interrogation of this genetic
interaction revealed that Faf deubiquitylated phosphory-
lated Par1, thereby enhancing its activity [78]. These
observations indicate that USP9X is involved in multiple
aspects of neural development. Not surprisingly, USP9X
has now been implicated both directly by mutation or
indirectly in a number of human neurodevelopmental and
neurodegenerative disorders (see below).
USP9X in disease
Many of the above descriptions on the molecular, cell and
developmental processes regulated by USP9X have also
been described in the context of pathological mechanisms
underlying various human diseases. In line with these roles,
recent investigations of neurodevelopmental and neurode-
generative disorders as well as cancer have revealed the
involvement of USP9X (Fig. 3). Investigations of these
disorders help in understanding the normal roles of
USP9X, and reciprocally appreciating the diverse roles of
USP9X will provide insights into disease development.
USP9X in neurodevelopmental disorders
and neurodegeneration
Consistent with its functions during mouse embryonic
brain development, USP9X has been implicated in a
number of human neurodevelopmental disorders. Three
USP9X mutations (2 missense and 1 truncating) have been
associated with X-linked intellectual disability [18, 79].
Functional interrogation of these mutations revealed that
they were loss of function, in that the reductions in axonal
growth and neuronal migration observed in mouse neurons
lacking Usp9x could be rescued by human wild-type
USP9X, but not the mutated forms [18]. That all three
mutations are located in the protein’s C-terminal region
suggests it harbours functions important to neural devel-
opment, and in particular axonal growth and neural
migration. Additional indirect evidence for the involve-
ment of USP9X in neurodevelopmental disorders comes
from its interaction with doublecortin (DCX). Mutations in
DCX cause defective neuronal growth and migration
leading to lissencephaly in males and sub-cortical band
heterotopia in females, with associated epilepsy and intel-
lectual disability features [80, 81]. Importantly, one such
mutation in DCX specifically disrupts the DCX–USP9X
interaction whilst maintaining others, suggesting that the
interaction is critical [82]. Reciprocally, the disruption of
DCX–USP9X interaction may underlie pathology resulting
from USP9X mutations; the mutations cluster within the
USP9X C-terminus, which is known to bind DCX and
mutant USP9X proteins that fail to co-localise with DCX in
the axonal growth cones. Intriguingly, both USP9X and
DCX knockout mice models display similar neuronal mi-
gration defects [64, 83, 84]. Still, other USP9X interactions
may also be affected by the mutations. For example, the
C-terminus of USP9X is also known to bind to Smurf1
[65], and thus deregulation of TGFb signalling could
similarly contribute to the axonal growth defects, as has
been reported in neurons isolated from Usp9x knockout
mice [64]. With the advance in high throughput genetic
sequencing technologies, enquiries into patients with var-
ious neurodevelopmental disorders may provide further
evidence of the involvement of USP9X [85].
Several lines of evidence suggest that USP9X also plays
a significant role in the aetiology of neurodegenerative
diseases. The presence of neuronal cytoplasmic inclusions
composed of an accumulation of ubiquitylated proteins is a
distinctive characteristic of neurodegenerative disorders
such as Alzheimer’s, Parkinson’s and Huntington’s dis-
ease. Understanding the balance of ubiquitylation and
deubiquitylation is critical for treatment. a-synuclein ag-
gregation within Lewy bodies is a pathological hallmark of
both Parkinson’s disease (PD) and diffuse Lewy body
disorder. In the brain tissues of PD patients, USP9X
colocalises with a-synuclein inclusions, and in vitro studies
show a functional interaction; whilst monoubiquitylated a-
synuclein is degraded by the proteasome, USP9X deubiq-
uitylation of a-synuclein directs its degradation by the less
efficient autophagy pathway [86]. In PD patients where
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proteasomal inhibition is a feature, reduced levels of
USP9X is also found, which may explain the accumulation
of toxic, monoubiquitylated a-synuclein [87]. In the MPTP
(1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine)-induced
acute PD mouse model, however, USP9X expression was
significantly upregulated in all areas of the brain, perhaps
reflecting a cellular response to toxicity [87]. A role for
USP9X in the degradation of accumulated proteins has also
been suggested in Huntington’s and Alzheimer’s disease.
USP9X interacts with Htt from mouse brains of both wild
type and YAC128 Alzheimer’s model (transgenic mice
expressing human Huntingtin protein) [88]. In a
Drosophila Alzheimer’s model, overexpression of faf was
found to enhance toxicity of Ab-42 expression [78]. Thus,
it will be interesting to investigate further the role of
USP9X in neurodegenerative diseases characterised by
protein accumulation. USP9X has also been linked to
spinal muscle atrophy (SMA), a hereditary disorder re-
sulting from reduced expression of survival motor neuron
(SMN). Here, USP9X activity is thought to be protective as
it directly interacts with SMN in 293T cells protecting it
from proteasomal degradation and also regulates the pro-
tein levels of core members of the SMN complex [42]. In
aggregate, it is clear that USP9X could contribute to the
expressivity and outcomes of neurodegenerative disorders;
however, the evidence thus far has been mostly associative.
Functional interrogation using animal models with sup-
portive human evidence is required to establish the actual
role that USP9X may play in neurodegeneration.
USP9X and cancer
Deubiquitylating enzymes play a major role in ho-
moeostasis and, not surprisingly, are increasingly
Fig. 3 Overview of the contribution of USP9X to development and
disease. USP9X (red) interacts with 35 known proteins (purple
triangles), many of which are substrates. The interaction between
USP9X and its binding partners is regulated by the sub-cellular
localisations of both (green circle). The outcomes of USP9X
interactions are known to control many cellular processes and
behaviour (orange circle), which likely underlie the involvement of
USP9X in development and disease processes. Each layer of USP9X
involvement (i.e. the concentric circles representing substrates,
localisation, cell behaviour and developmental and disease processes)
can be rotated (arrowheads) so as to find combinations of relevant
mechanisms. For example, the localisation of USP9X and AF6 at sites
of cell–cell adhesion is required for the polarity of blastomeres and
pre-implantation development, whilst the interaction of USP9X and
MCL1 in the cytoplasm results in the activation of the anti-apoptotic
pathways that can lead to tumour resistance against oncogenic
therapies
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implicated in the initiation and/or progression of cancer. A
comprehensive in situ hybridisation analysis of nine human
cancers revealed that several DUBs, including USP9X, are
frequently dysregulated in cancers [89]. These results are
supported by our queries on the Oncomine Research edi-
tion (Table 2) and COSMIC database [90, 91] as well as
studies on prostate cancers [92]. USP9X expression is
significantly upregulated in ERG-positive prostate tumours
compared to ERG-negative and benign tumours [92]. In-
triguingly, USP9X deubiquitylates and stabilises ERG
protein levels in prostate cancer cells. In human osteosar-
coma cell line SaOS2 expressing prostate-specific antigen,
USP9X was also significantly upregulated [93]. Together,
these (and other) studies reveal that USP9X expression is
deregulated in cancers. Such knowledge may be of prog-
nostic value, as an increase in USP9X expression in
multiple myeloma patients was associated with poor
prognostic outcomes [24], and increased USP9X expres-
sion in oesophageal squamous cell carcinoma was
correlated with poor survival after radical surgery [94].
Conversely, in pancreatic ductal adenocarcinoma, decrease
in USP9X mRNA correlated with poor prognostic out-
comes [95]. Recently, it was shown that loss of USP9X
function prevented tamoxifen-induced proliferation arrest
in oestrogen receptor a-positive breast cancer cells [96].
Consistently, USP9X has been implicated as both an
oncogene and tumour suppressor, depending on the type
and stage of cancer (see below). Whilst few studies have
looked at the transcriptional regulation of USP9X gene
expression, it is interesting in this context that USP9X is a
p53 target [67]. Adding further complexity, a cancerous
p53 mutant has been shown to bind USP9X, revealing a
potentially interesting regulatory loop [97]. In addition to
gene expression changes, exome sequencing and recur-
rence testing show that USP9X is frequently altered in
many cancers. Of the 86 cancer types listed in cBioPortal
for Cancer Genomics [98, 99], mutations or copy number
variations in USP9X were found in 53 types (62 %), with
the frequency of USP9X within a single cancer type al-
terations found up to 13 %. USP9X alterations are even
more frequent in other cancers; for example, it was found
in 22 % of gingivo-buccal oral squamous cell carcinoma
(OSCC-GB) samples [100]. Comparisons of the frequency
of natural variation in USP9X alleles derived from control
individuals in the EXAC database and cancer samples
deposited in the COSMIC database (using the most con-
servative approach where all samples are assumed male to
derive USP9X allelic frequencies) reveal that cancer sam-
ples have 29 times more synonymous variation, but have
578 times more non-synonymous changes (missense, non-
sense and insertion/deletions). Many of these changes are
likely to be damaging, for example, whilst non-sense
variants are never found in control samples, they are found
at a frequency of 1 in every 518 cancer samples. Ongoing
large-scale cancer sequencing projects are predicted to
reveal further genetic evidence of the involvement of
USP9X in cancer.
Whilst the above evidence generally implicates roles in
cancer, more detailed functional investigations of USP9X’s
molecular interactions provide direct evidence and hints on
how USP9X can display both oncogenic and tumour sup-
pressor activities. One oncogenic function of USP9X
derives from its interaction with the anti-apoptopic protein
MCL1, which is highly expressed in cancers and associated
with resistance to chemotherapy [101–103]. USP9X deu-
biquitylation of MCL1 inhibits its proteasomal
degradation, thus promoting its anti-apoptotic functions. In
human follicular lymphomas, colon adenocarcinoma and
small cell lung carcinomas, increased USP9X expression
correlates with elevated MCL1 protein levels [24, 104].
Furthermore, the chemical inhibition of USP9X increased
the sensitivity of the human lung carcinoma lines A549 and
H1299 to an anti-apoptotic inhibitor (ABT-737, targets
BCL-xl, but not MCL1). The importance of the MCL1–
USP9X interaction extends to other cancer cells. In Jurkat
T lymphoma and K562 chronic myelogenous cells, USP9X
is enzymatically activated in response to ionising radiation
and causes MCL1 stabilisation, in turn inhibiting apoptosis
and resulting in radioresistance [105].
Conversely, USP9X has tumour suppressor functions via
its genetic interaction with Kras. Mutations in KRAS are
frequently found in pancreatic ductal adenocarcinoma
Table 2 Oncomine analysis for USP9X
Type of cancer Overexpressed Underexpressed
Cervical cancer 2/5 (40 %)
Colorectal cancer 6/25 (24 %)
Lymphoma 8/35 (23 %)
Other cancer 5/29 (17 %) 1/29 (3 %)
Kidney cancer 3/20 (15 %)
Breast cancer 5/43 (12 %) 3/43 (7 %)
Prostate cancer 2/18 (11 %) 1/18 (6 %)
Brain and CNS cancer 2/26 (8 %) 6/26 (23 %)
Sarcoma 1/17 (6 %)
Bladder cancer 2/11 (18 %)
Melanoma 1/6 (17 %)
Ovarian cancer 2/13 (15 %)
Lung cancer 3/22 (14 %)
Leukaemia 2/25 (8 %)
Head and neck cancer 1/26 (4 %)
USP9X expression in different cancers (analysis: cancer versus nor-
mal). Set threshold P value\0.05; fold change[1.5; gene rank, top
10 %. Table represents ratio and percentage for overexpression and
underexpression in relation to the total number of analyses available
in the database
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(PDA), and expression of oncogenic KrasG12D mutation in
mouse pancreatic tissue initiates the development of PDA.
In these models, genetic inactivation of Usp9x (either by
insertional mutagenesis or Pdx1-Cre mediated deletion)
was found to enhance oncogenic KrasG12D in accelerating
tumourogenesis and cancer progression [95]. Surprisingly,
the Pdx1-Cre/KRasG12D/Usp9x-/Y mice also developed
aggressive oral papillomas, likely due to additional Cre
recombinase activity in suprabasal keratinocytes [106]. In
mouse PDA cell lines, Usp9x depletion resulted in in-
creased transformation and decreased anoikis [95]. Whilst
the molecular link between Usp9x and Kras remains to be
revealed, reduced expression of the USP9X substrate ITCH
was observed in PDA cells lacking USP9X, and ITCH
overexpression could rescue the transformation and anoikis
phenotype, together suggesting ITCH as a likely mediator
of USP9X tumour suppressor function [95]. Both loss of
USP9X and ITCH were associated with PDA in humans.
Overall, the evidence suggests that the role of USP9X in
cancer is tissue specific and implicates USP9X as a
clinically relevant candidate warranting further
investigation.
Conclusions and future directions
The regulation of various proteins by USP9X is a complex
and dynamic process that is central to cellular processes
including cell adhesion, polarity, vesicular trafficking,
signal transduction and apoptosis. Through these roles,
USP9X has been found to regulate developmental pro-
cesses, and deregulated USP9X function is implicated in
neurodevelopmental and neurodegenerative diseases as
well as various cancers. Whether such knowledge can
translate into clinical practice remains unanswered. Ad-
dressing this question is challenging and will require
reciprocal investigations between the normal and patho-
logical roles of USP9X.
One major challenge will be to understand the devel-
opmental, cellular (including subcellular) and molecular
context of USP9X-regulated processes. USP9X interacts
with a large number of substrates and has remarkable po-
tential to coordinate the inputs of multiple signalling
pathways with cellular responses. However, its requirement
in any process will be underpinned by the context in which
it exists. This fact is highlighted by the apparent contra-
diction is some reported USP9X roles, for example, both
promoting and inhibiting TGFb signalling, acting in both
pro- and anti-apoptotic pathways and displaying both
oncogenic and tumour suppressor functions. Dissecting
which particular interactions (or sets of interactions) are
critically required for any given processes and in what
context will be crucial. This will require an in-depth
understanding of what governs the ability of USP9X to
interact with substrates and proteins, and involve resolution
of its protein structure. The complex and dynamic ex-
pression of USP9X and its substrates suggests that this task
will be a daunting one, but investigations of the effects of
rare genetic variants associated with neurological disorders
have begun to provide important insights and should re-
main a focus of future research.
The second major challenge will be the manipulation of
USP9X in a context-specific manner to provide therapeutic
avenues. Current approaches have employed WP1130, a
small molecule DUB inhibitor that targets USP9X along
with USP5, USP14 and UCH-L5 [107]. However, the
mechanism of WP1130 inhibition of DUBs is currently
unknown and there are no USP9X-specific inhibitors. Fur-
thermore, such an approach lacks the required contextual
specificity and, whilst perhaps offering beneficial disruption
of a disease-relevant process, will likely be detrimental to
other USP9X-regulated processes leading to unwanted side
effects. Possible solutions to this problem will lie in the
discovery of what regulates USP9X expression, sub-cellular
localisation and enzymatic activity in particular cells. For
example, it is known that USP9X utilises alternative 30UTR
sequences in response to neuronal activity [108], and this
might provide a specific miRNA-based therapeutic target for
treatment in neurological disorders such as epilepsy. Like-
wise, the transcription factor p53 has been reported to
influence USP9X expression [67], which might provide an
avenue to target certain cancers. Post-translational modifi-
cation of USP9X such as phosphorylation might also offer
new approaches to alter its activity in specific contexts. Once
again, these knowledge gaps should be approached by
studying the involvement of USP9X in normal and diseased
states.
The extraordinary level of conservation and involve-
ment in fundamental cell and developmental processes
have identified USP9X as a molecule of great importance.
The complexities of its function and regulation will be
challenging to dissect; however, this accomplishment will
be accompanied by new exciting insights into human bi-
ology and disease.
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